News & Views
Telix Japan is pleased to announce it will be presenting at the Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM-JSNMT2020) to be held 12-14th November 2020 at…
Read more
Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate…
Read more
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab)…
Read more
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical…
Read more
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of…
Read more
Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased…
Read more
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of…
Read more
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of…
Read more
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer…
Read more
Telix announces it has entered into a strategic collaboration agreement with Varian Medical…
Read more